生物小分子钒配合物抑制蛋白酪氨酸磷酸酶活性研究

钒化合物治疗糖尿病机理研究表明其与蛋白酪氨酸磷酸酶的酶活抑制有一定关系。本文分别研究了生物小分子配体与氧钒离子在20:1配比条件下形成的生物小分子钒配合物及其对蛋白酪氨酸磷酸酶的抑制作用和选择性。结果表明氨基酸与氧钒离子配合形成2:1的配合物, 而抗坏血酸及多羧酸与氧钒离子配合形成1:1的配合物。它们对蛋白酪氨酸磷酸酶抑制作用显示, 大部分生物小分子氧钒配合物对PTP1B表现强烈的抑制作用, IC₅₀值在0.12~0.63 μmol·L^-1之间。化合物[VO(Phe)₂]表现最强的抑制作用, IC₅₀值为0.07 μmol·L^-1。而[VO(Arg)₂]、[VO(Oxalate)]、[VO(Nitrilotriacetate)]和[VO(Citrate)]则呈现较弱的抑制, IC₅₀值分别为1.05、1.41、9.90和21.5 μmol·L^-1。对PTP1B, TCPTP, HePTP以及SHP-1的抑制作用表明配体的结构不仅影响氧钒配合物对蛋白酪氨酸磷酸酶的抑制效率同时也影响其选择性。     

多苯并咪唑锌配合物抑制蛋白酪氨酸磷酸酶(PTPs)的活性

本文报道了5种多苯并咪唑锌配合物,即[Zn(TDB)₂]Cl₂(1)、[Zn(NTB)Cl]Cl (2)、[Zn(EDTB)]Cl₂(3)、[Zn₂(EGTB)Cl₂]Cl₂(4)和[Zn₂(DTPB)Cl₃]Cl (5),其中TDB=1,2-二(2-苯并咪唑)-1,2-二羟基乙烷、NTB=N,N,N-三(2-甲基苯并咪唑)胺、EDTB=N,N,N'',N''-四(2-苯并咪唑亚甲基)-1,2-乙二胺、EGTB=N,N,N'',N''-四(2-苯并咪唑甲基)-1,4-二乙胺基乙二醚以及DTPB=N,N,N'',N",N"-五(2-苯并咪唑甲基)-二乙三胺,对5种蛋白酪氨酸磷酸酶(PTP1B、TCPTP、PTP-MEG2、SHP-1和SHP-2)的抑制作用,结果显示这些配合物强烈抑制PTP1B的活性,其IC₅₀值在0.15~0.28μmol·L^-1范围内,但对PTP-MEG2和SHP-1抑制较弱,几乎不抑制SHP-2,而配合物1、3、5对与PTP1B高度同源的TCPTP的抑制明显强于2和4,因而2和4对PTP1B表现较强的选择性,对PTP1B抑制活性是TCPTP的7~12倍、PTP-MEG2的10~15倍、SHP-1的20~40倍,大约是SHP-2的1000倍,表明配合物的结构影响其对PTP1B的选择性。酶促动力学实验显示2和4对高度同源的PTP1B和TCPTP抑制类型不同,对PTP1B的抑制为竞争型,而对TCPTP的抑制为非竞争型,推测其选择性可能与其抑制方式有关。荧光滴定表明2和4与PTP1B和TCPTP发生了1:1结合作用。结合常数分别为1.12×10⁶、5.47×10⁵、1.19×10⁶和4.95×10⁵ L·mol^-1,表明它们与PTP1B的结合能力强于TCPTP,与它们对这两种酶的抑制能力一致。     

多苯并咪唑锌配合物抑制蛋白酪氨酸磷酸酶(PTPs)的活性

本文报道了5种多苯并咪唑锌配合物,即[Zn(TDB)_2]Cl_2(1)、[Zn(NTB)Cl]Cl(2)、[Zn(EDTB)]Cl_2(3)、[Zn_2(EGTB)Cl_2]Cl_2(4)和[Zn_2(DTPB)Cl_3]Cl(5),其中TDB=1,2-二(2-苯并咪唑)-1,2-二羟基乙烷、NTB=N,N,N-三(2-甲基苯并咪唑)胺、EDTB=N,N,N′,N′-四(2-苯并咪唑亚甲基)-1,2-乙二胺、EGTB=N,N,N′,N′-四(2-苯并咪唑甲基)-1,4-二乙胺基乙二醚以及DTPB=N,N,N′,N″,N″-五(2-苯并咪唑甲基)-二乙三胺,对5种蛋白酪氨酸磷酸酶(PTP1B、TCPTP、PTP-MEG2、SHP-1和SHP-2)的抑制作用,结果显示这些配合物强烈抑制PTP1B的活性,其IC_(50)值在0.15~0.28μmol·L~(-1)范围内,但对PTP-MEG2和SHP-1抑制较弱,几乎不抑制SHP-2,而配合物1、3、5对与PTP1B高度同源的TCPTP的抑制明显强于2和4,因而2和4对PTP1B表现较强的选择性,对PTP1B抑制活性是TCPTP的7~12倍、PTP-MEG2的10~15倍、SHP-1的20~40倍,大约是SHP-2的1 000倍,表明配合物的结构影响其对PTP1B的选择性。酶促动力学实验显示2和4对高度同源的PTP1B和TCPTP抑制类型不同,对PTP1B的抑制为竞争型,而对TCPTP的抑制为非竞争型,推测其选择性可能与其抑制方式有关。荧光滴定表明2和4与PTP1B和TCPTP发生了1∶1结合作用。结合常数分别为1.12×10~6、5.47×10~5、1.19×10~6和4.95×10~5 L·mol~(-1),表明它们与PTP1B的结合能力强于TCPTP,与它们对这两种酶的抑制能力一致。     

水杨醛缩芳胺席夫碱铜(Ⅱ)配合物抑制蛋白酪氨酸磷酸酶活性研究

为了探讨席夫碱配体上取代基变化对其配合物抑制蛋白酪氨酸磷酸酶(PTPs)活性的影响,合成表征了水杨醛缩芳胺席夫碱铜(Ⅱ)配合物[Cu(X-pimp)₂](X=Cl,Br和Acetyl),用紫外光谱滴定和pH电位滴定研究了[Cu(Cl-pimp)₂]的溶液结构,并测定了3个配合物抑制4种PTPs活性的IC₅₀值。结果表明它们都能够有效抑制PTP1B和TCPTP(0.20μmol·L^-1< IC₅₀< 0.31μmol·L^-1),但对SHP-1的抑制较弱且对SHP-2几乎无抑制作用。分析并与文献结果比较发现,席夫碱配体上苯胺对位取代基类型的改变不会显著影响其抑制作用,但取代基位置的改变可能会影响其选择性。稳态动力学研究表明[Cu(Cl-pimp)₂]能够非竞争性抑制PTP1B活性,而荧光光谱实验表明二者形成了键合常数为9.3×10⁶L·mol^-1的1:1复合物。我们推测,配合物可能结合在PTP1B非活性区域,间接导致活性中心结构变化,从而抑制其活性。     

含氮杂环氧钒配合物对PTP1B和ALP的抑制活性研究

蛋白酪氨酸磷酸酶1B (protein tyrosine phosphatase 1B, PTP1B)是当前开发治疗糖尿病药物的优秀靶标, 也是钒配合物抗糖尿病作用相关的重要靶蛋白. 研究了三种含氮平面杂环螯合配体2,2’-联咪唑(L1), 2,2’-联吡啶(L2), 1,10-邻菲咯啉(L3)的氧钒配合物对PTP1B以及碱性磷酸酶(alkaline phosphatase, ALP)的体外抑制作用. 结果表明, 1∶1和2∶1型配位的氧钒化合物均表现出对PTP1B较强的抑制活性, IC50值在120～260 nmol/L间, 抑制能力接近双麦芽酚氧钒配合物(BMOV). 抑制动力学实验表明这些氧钒配合物对PTP1B的抑制模式均为竞争性抑制, 抑制常数在20～160 nmol/L. 其对PTP1B抑制活性较ALP高103倍, 表明氧钒配合物对两种磷酸酶的抑制具有一定的选择性.     

N-(2-吡啶甲基)-L-丝氨酸铜配合物的合成、晶体结构及抑制蛋白酪氨酸磷酸酶活性

在甲醇溶液中, 还原希夫碱HL[N-(2-吡啶甲基)-L-丝氨酸]与CuCl₂·2H₂O以摩尔比1∶1反应, 得到1个新的中性单核铜配合物[CuLCl(H₂O)](Ⅰ). 通过X射线单晶衍射、 元素分析、 红外光谱、 电喷雾质谱和粉末X射线衍射分析等对其进行了表征. 晶体结构分析表明, 在该配合物中还原希夫碱以三齿双螯合环配位到中心铜离子, 同时氯离子和溶剂水分子也参与配位, 形成1个具有四方锥构型的五配位铜(Ⅱ)配合物, 该配合物通过分子间弱相互作用连接成二维超分子结构. 生物活性测试结果表明, 配合物Ⅰ能有效抑制蛋白酪氨酸磷酸酶1B(PTP1B)和T细胞蛋白酪氨酸磷酸酶(TCPTP), IC₅₀值分别为0.32和0.45 μmol/L.     

过氧钒配合物抑制朊蛋白淀粉样肽的纤维形成

采用荧光光谱(FS)、核磁共振(NMR)、电喷雾离子化质谱(ESI-MS)和透射电镜(TEM)方法研究过氧钒配合物(NH₄)[VO(O₂)₂(bipy)]·4H₂O(1)和(NH₄)[VO(O₂)₂(phen)]·2H₂O(2)与朊蛋白淀粉样肽PrP106-126的突变体M109F肽的相互作用。结果表明,过氧钒配合物可直接与M109F肽结合,并通过甲硫氨酸112的氧化作用来达到对M109F肽聚集的抑制作用。与配合物2比较,配合物1显示出对M109F肽更好的抑制作用;过氧钒配合物1和2都可以有效地降低M109F肽诱导的细胞毒性。本工作为潜在金属药物用于神经退行性疾病的研究提供了基础数据。     

钒邻苯二酚双齿配合物从头算研究

运用Gaussian 94W量子化学程序包,采用LanL2DZ基组,对钒邻苯二酚双齿配合物结构单元V(cat)₃^n-(n=1,2)进行从头算研究。探讨这些配合物的稳定性、分子轨道能量、原子净电荷布居规律以及处于前沿的一些分子轨道的组成特征,为过渡金属双齿配合物的合成、分子组装及其在酶和蛋白质中的活性部位研究提供理论参考。     

小分子配合物电致发光材料研究进展

本文简述了有机电致发光及有机发光二极管的基本原理 ;概述了小分子配合物电致发光材料的最新研究进展 ,讨论了它们的光电性质、器件的发光效率和稳定性 ;展望了小分子配合物电致发光材料的前景.     

钒酰—亚胺配合物的ESR波谱研究

本文研究了二(邻羟亚苄基胺)钒酰配合物在一系列有机溶剂中的ESR波谱。室温下,g值在不同溶剂中的变化有如下次序:CHCl_3>py>CH_3CN>THF>CH_3OH,α值的趋势为:THF>CH_3CN>CHCl_3>py≈CH_3OH.通过在THF及py溶剂中的低温ESR波谱得到的g_(11)、g_1、A_(11)、A_1、计算出了β_2~(*2)、K、β_1~(*2)、β_1~(′*)、ε_π~*、ε_π~(′*)等键参数,并讨论了溶剂对配合物电子结构的影响.     

Thermal Behaviour of Oxovanadium(IV) Complexes of Halogenated Derivatives of 8-hydroxyquinoline

The thermal behaviour of a series of oxovanadium(IV) complexes of halogenated derivatives of 8-hydroxyquinoline was investigated by means of TG and DTA measurements in oxygen atmosphere. V₂O₅ was the final pyrolysis residue in all cases.This revised version was published online in November 2005 with corrections to the Cover Date.     

Synthesis,Characterization and Antimicrobial Activity of Oxovanadium(IV) Complexes of Schiff Base Hydrazones Containing Quinoxaline Moiety

The oxovanadium(IV) complexes of the Schiff base hydrazones, synthesized from 3‐hydrazinoquinoxaline‐2‐one (HQO) with salicylaldehyde (HSHQO), o‐hydroxyacetophenone (HHAHQO), dehydroacetic acid (HDHAHQO) and o‐nitrobenzaldehyde (NBHQO) were synthesized and characterized on the basis of analytical, conductance, magnetic moment, infrared, NMR, ESR and electronic spectral data. The ligands HSHQO, HDHAHQO behaved as monobasic tridentate ONN donors through phenolic oxygen, azomethine nitrogens. The ligand HAHQO acted as a monobasic bidentate ON donor through the phenolic oxygen, azomethine (free) nitrogen and the ligand NBHQO acted as neutral bidentate ON donor through oxygen of the nitro group and azomethine (free) nitrogen.     

席夫碱双氧钒(Ⅴ)配合物的合成、结构及其抑制幽门螺旋杆菌脲酶研究

本文合成了2个双氧钒(Ⅴ)配合物,[VO2L1](1)和[VO2L2]2(2)(L1=4-氯-2-[(2-苯胺基乙亚胺基)甲基]苯酚盐;L2=4-[2-(2-{[1-(5-氯-2-羟基苯基)甲亚胺基]胺基}乙胺基)乙亚胺基]-2-戊酮),并通过物理化学方法和单晶X-射线衍射表征了它们的结构。在单核配合物1中,V原子采取畸变的四方锥配位构型,在双核配合物2中,V原子采取八面体配位构型。研究了这2个配合物对幽门螺旋杆菌脲酶的抑制活性。在浓度为100μmol.L-1时,配合物1和2对脲酶的抑制率分别为(52.1±1.8)%和(34.2±3.3)%。还做了配合物和幽门螺旋杆菌脲酶的分子对接研究。配合物的结构和其抑制脲酶活性的关系表明,配合物分子的尺寸和形状对脲酶的抑制作用具有重要影响。     

Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2)

Natural products have continued to offer tremendous opportunities for drug development, as they have long been used in traditional medicinal systems. SHP2 has served as an anticancer target. To identify novel SHP2 inhibitors with potential anticancer activity, we screened a library containing 658 natural products. Polyphyllin D was found to selectively inhibit SHP2 over SHP1, whereas two other identified compounds (echinocystic acid and oleanolic acid) demonstrated dual SHP1 and SHP2 inhibition. In a cell-based assay, polyphyllin D exhibited cytotoxicity in Jurkat cells, an acute lymphoma leukemia cell line, whereas the other two compounds were ineffective. Polyphyllin D also decreased the level of phosphorylated extracellular signal-regulated kinase (p-ERK), a proliferation marker in Jurkat cells. Furthermore, knockdown of protein tyrosine phosphatase (PTP)N6 (SHP1) or PTPN11 (SHP2) decreased p-ERK levels. However, concurrent knockdown of PTPN6 and PTPN11 in Jurkat cells recovered p-ERK levels. These results demonstrated that polyphyllin D has potential anticancer activity, which can be attributed to its selective inhibition of SHP2 over SHP1.     

Synthesis,Characterization, and Antibacterial Studies of Oxovanadium(IV) Complexes with Thiazole-Derived Schiff Bases

Oxovanadium(IV) complexes of Schiff bases, derived from 2-amino-4-phenyl thiazole/substituted 2-amino-4-phenyl thiazoles and thiophene-2-aldehyde have been synthesized and characterized on the basis of elemental analysis, molar conductance measurements, magnetic susceptibility data, and UV-visible, and IR spectral studies. All the complexes are monomeric possessing a 1:2 (metal:ligand) stoichiometry. On the basis of these data, a square pyramidal geometry has been assigned for the complexes. A few complexes have been subjected to thermal decomposition studies. The ligands and their metal complexes have been screened for their antibacterial activities.

Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental file.     

Glucose-lowering A ivity of Amino Acid- phosphonic Acid Oxovanadium Complexes and Its Interaction with DNA

Vanadium has well-documented lowering glucose properties both in vitro and in vivo. The design of new oxovanadium（IV） coordination compounds, intended for use as insulin-enhancing agents in the treatment of diabetes mellitus, can potentially benefit from a synergistic approach, in which the whole complex has more than an additive effect from its component parts. Biological testing with oxovanadium（IV） organic phosphonic acid, for insulin-enhancing potential included acute administration, by oral gavage in streptozotocin （STZ） diabetic rats. The complexes of oxovanadium（IV） amino acid-N-phosphonic acid exhibit higher lowering glucose activity in vivo. The interaction of the complexes of oxovanadium（IV） amino acid-N-phosphonic acid with DNA was investigated by agarose gel electrophoresis. The results indicated that these complexes have strong interaction with DNA.     

含水杨醛缩对硝基苯甲酰腙的钒酰配合物和钴配合物的合成和晶体结构

本文合成了含水杨醛缩对硝基苯甲酰腙(简写为H2L)的钒酰配合物VOL(CH3OH)(CH3O)(1,C16H16N3O7V,Mr=413.26)和钴配合物[CoL(C5H5N)3]NO3C5H5N(2,C34H29N8O7Co,Mr=720.58)。配合物1属单斜晶系,空间群为P21/c,a=7.3253(3),b=18.8237(9),c=12.9014(5)?b=91.672(1),V=1778.2(1)3,Z=4,F(000)=848,m(MoKa)=0.603mm1,R=0.0470,wR=0.1312。配合物2属单斜晶系,空间群为P21/c,a=11.4196(8),b=17.157(1),c=17.081(1)?b=96.8233(9),V=3323.0(4)3,Z=4,F(000)=1488,m(MoKa)=0.578mm1,R=0.0455,wR=0.1311。在配合物1中,钒(V)原子由周围的酰氧基原子、配体L2的3个配位原子,去质子化甲醇的甲氧基原子和配位甲醇的氧原子配位,形成畸变的VO(ONO)(O)(O)八面体配位构型。晶体内每2个分子间通过氢键作用缔合成中心对称的分子对,OH…N氢键键长为2.861(4)?键角163.20。晶体中存在着弱p-p共轭作用。在配合物2中,钴(Ⅲ)原子由1个L2的3个配位原子和3个配位吡啶分子的3个氮原子配位,呈N4O2八面体配位构型。     

Redox Modulation of PTEN Phosphatase Activity by Hydrogen Peroxide and Bisperoxidovanadium Complexes

PTEN is a dual‐specificity protein tyrosine phosphatase. As one of the central tumor suppressors, a thorough regulation of its activity is essential for proper cellular homeostasis. The precise implications of PTEN inhibition by reactive oxygen species (e.g. H₂O₂) and the subsequent structural consequences remain elusive. To study the effects of PTEN inhibition, bisperoxidovanadium (bpV) complexes serve as important tools with the potential for the treatment of nerve injury or cardiac ischemia. However, their mode of action is unknown, hampering further optimization and preventing therapeutic applications. Based on protein crystallography, mass spectrometry, and NMR spectroscopy, we elucidate the molecular basis of PTEN inhibition by H₂O₂ and bpV complexes. We show that both molecules inhibit PTEN via oxidative mechanisms resulting in the formation of the same intramolecular disulfide, therefore enabling the reactivation of PTEN under reductive conditions.